Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.39 |
| ▸ | CTSG | P08311 | 5/20 | 0.39 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | CTRC | Q99895 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388290 | 0.93 | ELANE (0.37) | ELANECTSGALDH1A1TYMSKDM4E | |
| SCHEMBL6390026 | 0.89 | TYMS (0.35) | ALDH1A1TYMSKDM4EAURKAAURKB | |
| SCHEMBL6393866 | 0.85 | ELANE (0.39) | ELANECTSGPTPRBPBRM1TYMS | |
| SCHEMBL6390031 | 0.84 | ELANE (0.40) | ELANECTSGPTPRBPBRM1ALDH1A1 | |
| SCHEMBL6390574 | 0.82 | ELANE (0.38) | ELANECTSGTYMSAURKAAURKB | |
| SCHEMBL6395588 | 0.78 | AURKA (0.39) | ELANECTSGALDH1A1TYMSKDM4E | |
| SCHEMBL6395017 | 0.77 | MAPKAPK2 (0.38) | ELANECTSGALDH1A1TYMSKDM4E | |
| SCHEMBL6390631 | 0.77 | PTPRB (0.35) | PTPRBALDH1A1TYMS | |
| SCHEMBL6394547 | 0.76 | AURKA (0.35) | TYMSAURKAAURKB | |
| SCHEMBL6389628 | 0.76 | ELANE (0.38) | ELANECTSGTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050040373-A1 | Dopant and conductive polymer material therewith | MITSUI CHEMICALS, INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-6814888-B2 | FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR | MITSUI CHEMICALS, INC. (JP) | 2004-11-09 | — | — | US | disclosed |
| US-20030142462-A1 | Dopant agent and electroconductive polymer material comprising the same | MITSUI CHEMICALS, INC. (JP) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030142462-A1 | Dopant agent and electroconductive polymer material comprising the same | RPS6, H1-10, H1-0 | ELANE 2335/4885CTSG 2871/4885PTPRB 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.